nordazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 816 1088-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desmethyldiazepam
  • demethyldiazepam
  • demoxazepam
  • desalkylprazepam
  • N-Demethyldiazepam
  • nordazepam
  • nordiazepam
  • norprazepam
  • praxadium
An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.
  • Molecular weight: 270.72
  • Formula: C15H11ClN2O
  • CLOGP: 3.02
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 41.46
  • ALOGS: -4.09
  • ROTB: 1

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.06 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.79 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.45 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 46 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 99 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.954 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.631 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 83.946 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 15.101 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 7.280 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 16.380 % High 1
herg hERG pIC50 4.439 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.919 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 4.592 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 7.450 % High 1
kinase-safety-class EIF2AK3,GRK2,PDK1,PDK2,PDK4 5
kinase-selectivity-class GRK2 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.592 High 1
mh-clint Mouse hepatocyte intrinsic clearance 30.339 High 1
mppb Mouse plasma protein binding (% unbound) 10.950 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.832 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 9.760 % High 1
rh-clint Rat hepatocyte intrinsic clearance 19.634 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 60.490 % High 1
rppb Rat plasma protein binding (% unbound) 9.340 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 98.401 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1961 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 1167.09 114.59 381 1908 287465 90338693
Drug abuse 323.15 114.59 108 2181 82239 90543919
Asphyxia 307.31 114.59 63 2226 7040 90619118
Poisoning 244.20 114.59 60 2229 15157 90611001
Substance abuse 222.31 114.59 46 2243 5360 90620798
Completed suicide 196.98 114.59 88 2201 144970 90481188
Victim of sexual abuse 156.69 114.59 25 2264 670 90625488
Coma 137.92 114.59 56 2233 72576 90553582
Drug interaction 133.24 114.59 84 2205 276369 90349789
Patient uncooperative 122.98 114.59 18 2271 266 90625892

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 2537.23 107.16 1036 5800 228100 42386399
Drug abuse 1449.75 107.16 562 6274 104209 42510290
Aggression 539.41 107.16 218 6618 43945 42570554
Substance abuse 463.62 107.16 131 6705 8774 42605725
Asphyxia 307.85 107.16 94 6742 8232 42606267
Poisoning 304.39 107.16 107 6729 14592 42599907
Drug dependence 255.87 107.16 114 6722 28980 42585519
Depressed level of consciousness 240.65 107.16 128 6708 47842 42566657
Respiratory depression 239.54 107.16 96 6740 18772 42595727
Logorrhoea 239.16 107.16 61 6775 2746 42611753
Bradykinesia 238.22 107.16 70 6766 5366 42609133
Pulmonary oedema 225.34 107.16 127 6709 53145 42561354
Visceral congestion 223.14 107.16 47 6789 894 42613605
Dysarthria 218.93 107.16 113 6723 39694 42574805
Bradyphrenia 214.16 107.16 64 6772 5198 42609301
Brain oedema 189.77 107.16 78 6758 16249 42598250
Miosis 179.59 107.16 71 6765 13375 42601124
Abnormal behaviour 174.51 107.16 85 6751 26366 42588133
Overdose 159.39 107.16 133 6703 105131 42509368
Psychotic behaviour 133.87 107.16 31 6805 923 42613576
Drug interaction 127.07 107.16 183 6653 266816 42347683
Restlessness 118.81 107.16 68 6768 29181 42585318

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 3610.93 92.86 1362 7667 479193 110101077
Drug abuse 1848.33 92.86 647 8382 176764 110403506
Substance abuse 738.85 92.86 177 8852 12286 110567984
Aggression 709.04 92.86 241 8788 58969 110521301
Asphyxia 606.13 92.86 155 8874 14060 110566210
Poisoning 559.89 92.86 170 8859 28935 110551335
Drug dependence 314.44 92.86 127 8902 49893 110530377
Respiratory depression 312.19 92.86 112 8917 31889 110548381
Logorrhoea 286.24 92.86 69 8960 4888 110575382
Bradykinesia 281.95 92.86 80 8949 10708 110569562
Abnormal behaviour 272.75 92.86 107 8922 38932 110541338
Bradyphrenia 270.91 92.86 79 8950 11649 110568621
Pulmonary oedema 260.44 92.86 138 8891 100521 110479749
Visceral congestion 256.30 92.86 50 8979 1295 110578975
Overdose 255.82 92.86 185 8844 233609 110346661
Dysarthria 251.17 92.86 127 8902 83994 110496276
Drug interaction 244.42 92.86 249 8780 499934 110080336
Coma 237.37 92.86 137 8892 117732 110462538
Depressed level of consciousness 224.73 92.86 130 8899 112148 110468122
Accidental overdose 224.17 92.86 101 8928 51733 110528537
Miosis 210.79 92.86 76 8953 21907 110558363
Brain oedema 192.00 92.86 78 8951 31020 110549250
Completed suicide 176.60 92.86 151 8878 242230 110338040
Patient uncooperative 148.55 92.86 30 8999 930 110579340
Restlessness 144.97 92.86 77 8952 56182 110524088
Psychotic behaviour 142.31 92.86 31 8998 1394 110578876
Victim of sexual abuse 127.31 92.86 24 9005 515 110579755
Accidental death 125.68 92.86 36 8993 4973 110575297
Drug use disorder 120.74 92.86 48 8981 18026 110562244
Intentional overdose 120.44 92.86 94 8935 132407 110447863
Substance use disorder 116.47 92.86 37 8992 7253 110573017
Victim of crime 110.15 92.86 25 9004 1358 110578912
Intentional product misuse 103.19 92.86 86 8943 132818 110447452
Pulmonary congestion 101.88 92.86 50 8979 30916 110549354
Drug screen positive 100.20 92.86 32 8997 6378 110573892
Sudden death 97.39 92.86 45 8984 24350 110555920
Agitation 93.71 92.86 76 8953 112975 110467295

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05BA16 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:50268 GABA modulator
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

N05BA Benzodiazepine derivatives 23 drugs
adinazolamalprazolambentazepambromazepamcamazepamchlordiazepoxideclobazamclorazepateclotiazepamcloxazolamdiazepamethyl loflazepate show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.98 acidic
pKa2 3.43 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Gamma-aminobutyric acid type B receptor subunit 2 GPCR IC50 8.03 WOMBAT-PK
Gamma-aminobutyric acid receptor subunit rho-2 Ion channel WOMBAT-PK
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel IC50 6.28 WOMBAT-PK
GABA-A receptor; anion channel Ion channel Ki 4.14 CHEMBL

External reference:

IDSource
N0000166921 NUI
D08283 KEGG_DRUG
3155 RXNORM
C0011279 UMLSCUI
CHEBI:111762 CHEBI
CHEMBL523 ChEMBL_ID
D003708 MESH_DESCRIPTOR_UI
DB14028 DRUGBANK_ID
4400 INN_ID
67220MCM01 UNII
2997 PUBCHEM_CID
005387 NDDF
96232003 SNOMEDCT_US

Pharmaceutical products:

None